CY1120348T1 - Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων - Google Patents

Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Info

Publication number
CY1120348T1
CY1120348T1 CY20181100630T CY181100630T CY1120348T1 CY 1120348 T1 CY1120348 T1 CY 1120348T1 CY 20181100630 T CY20181100630 T CY 20181100630T CY 181100630 T CY181100630 T CY 181100630T CY 1120348 T1 CY1120348 T1 CY 1120348T1
Authority
CY
Cyprus
Prior art keywords
disease
suppliers
terrain
inhibitors
aryl
Prior art date
Application number
CY20181100630T
Other languages
English (en)
Inventor
Emily M. Stocking
Wolfgang Wrasidlo
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120348(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CY1120348T1 publication Critical patent/CY1120348T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ορισμένες ενώσεις αμιδίων ετεροαρυλίου, φαρμακευτικές συνθέσεις περιέχοντας αυτές, και μεθόδους χρήσεις αυτών, που συμπεριλαμβάνουν μεθόδους για πρόληψη, αντιστροφή, επιβράδυνση ή αναστολή συσσωμάτωσης πρωτεϊνών, και μεθόδους αγωγής παθήσεων που συσχετίζονται με συσσωμάτωση πρωτεϊνών, που συμπεριλαμβάνουν νευροεκφυλιστικές παθήσεις όπως είναι η νόσος του Πάρκινσον, η νόσος του Αλτσχάϊμερ, η πάθηση σωμάτων Lewy, η νόσος του Πάρκινσον με άνοια, η κροταφομετωπιαία άνοια, η Νόσος του Χάντινγκτον, η αμυοτροφική πλευρική σκλήρυνση, και η ατροφία πολλαπλών συστημάτων, και ο καρκίνος και το μελάνωμα.
CY20181100630T 2014-01-29 2018-06-15 Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων CY1120348T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
CY1120348T1 true CY1120348T1 (el) 2019-07-10

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100630T CY1120348T1 (el) 2014-01-29 2018-06-15 Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
CY20201100682T CY1123374T1 (el) 2014-01-29 2020-07-24 Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100682T CY1123374T1 (el) 2014-01-29 2020-07-24 Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Country Status (37)

Country Link
US (3) US9738635B2 (el)
EP (2) EP3099684B8 (el)
JP (2) JP6619741B2 (el)
KR (1) KR102383038B1 (el)
CN (2) CN106132960B (el)
AP (1) AP2016009347A0 (el)
AU (1) AU2015211119B2 (el)
BR (2) BR112016017344B1 (el)
CA (1) CA2937967C (el)
CL (1) CL2016001918A1 (el)
CR (1) CR20160394A (el)
CY (2) CY1120348T1 (el)
DK (2) DK3348556T3 (el)
EA (1) EA032374B1 (el)
EC (1) ECSP16070327A (el)
ES (2) ES2675301T3 (el)
HK (1) HK1231470A1 (el)
HR (2) HRP20180813T1 (el)
HU (2) HUE040274T2 (el)
IL (1) IL246987B (el)
LT (2) LT3099684T (el)
ME (1) ME03800B (el)
MX (1) MX2016009896A (el)
MY (1) MY187450A (el)
NZ (1) NZ722487A (el)
PE (1) PE20161393A1 (el)
PH (1) PH12016501493A1 (el)
PL (2) PL3348556T3 (el)
PT (2) PT3348556T (el)
RS (2) RS57533B1 (el)
SA (1) SA516371579B1 (el)
SG (1) SG11201606108RA (el)
SI (2) SI3348556T1 (el)
TR (1) TR201809440T4 (el)
UA (1) UA118209C2 (el)
WO (1) WO2015116663A1 (el)
ZA (1) ZA201605246B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57533B1 (sr) 2014-01-29 2018-10-31 Ucb Biopharma Sprl Heteroaril amidi kao inhibitori proteinske agregacije
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性***的药物
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
ES2918048T3 (es) * 2017-01-26 2022-07-13 UCB Biopharma SRL Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
US10889584B2 (en) * 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
WO2018206778A1 (en) * 2017-05-12 2018-11-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
JP2020529432A (ja) * 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. 微生物により誘発されるアミロイドの阻害剤
CA3079831A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
EP3841100A1 (en) 2018-08-20 2021-06-30 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2023125376A1 (zh) * 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2024094731A1 (en) * 2022-11-02 2024-05-10 Ac Immune Sa Novel compounds for the diagnosis of tdp-43 proteinopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
BRPI0417820A (pt) * 2003-12-19 2007-03-27 Bristol Myers Squibb Co heterociclos azabicìclicos como moduladores de receptor canabinóide
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
ME01788B (me) * 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
JP2008513386A (ja) * 2004-09-20 2008-05-01 ４エスシー アーゲー 新規な複素環式ＮＦ−κＢ阻害剤
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
US20100168102A9 (en) 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
NZ588971A (en) * 2005-07-29 2012-06-29 4Sc Discovery Gmbh Novel heterocyclic NF-kappaB inhibitors
MX2008011696A (es) * 2006-03-15 2008-11-12 4Sc Ag Inhibidores de nf-kb heterociclicos novedosos.
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
CA2776480A1 (en) 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
BR112012014807A2 (pt) * 2009-12-16 2017-06-27 Neuropore Therapies Inc "compostos adequados para o tratamento de sinucleopatias"
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
EP2830608B8 (en) 2012-03-28 2020-01-15 UCB Biopharma SRL Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
AU2013290361A1 (en) 2012-07-16 2015-02-05 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
RS57533B1 (sr) 2014-01-29 2018-10-31 Ucb Biopharma Sprl Heteroaril amidi kao inhibitori proteinske agregacije
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US10889584B2 (en) 2017-01-26 2021-01-12 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas

Also Published As

Publication number Publication date
US20190308965A1 (en) 2019-10-10
LT3099684T (lt) 2018-06-25
WO2015116663A8 (en) 2016-09-15
HK1231470A1 (zh) 2017-12-22
HRP20180813T1 (hr) 2018-07-27
EP3099684B1 (en) 2018-04-04
PL3348556T3 (pl) 2020-11-02
AU2015211119B2 (en) 2019-05-30
CA2937967C (en) 2022-07-26
MX2016009896A (es) 2017-01-11
CN106132960A (zh) 2016-11-16
ZA201605246B (en) 2022-05-25
ES2808978T3 (es) 2021-03-02
IL246987A0 (en) 2016-09-29
BR122018001892B1 (pt) 2023-05-02
JP6619741B2 (ja) 2019-12-11
PH12016501493B1 (en) 2017-02-06
SI3099684T1 (en) 2018-08-31
HUE040274T2 (hu) 2019-03-28
SI3348556T1 (sl) 2020-10-30
KR20160113287A (ko) 2016-09-28
SA516371579B1 (ar) 2019-07-16
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
PH12016501493A1 (en) 2017-02-06
KR102383038B1 (ko) 2022-04-05
PT3348556T (pt) 2020-07-27
DK3099684T3 (en) 2018-07-16
RS57533B1 (sr) 2018-10-31
EA201691529A1 (ru) 2017-01-30
CR20160394A (es) 2016-11-01
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
CA2937967A1 (en) 2015-08-06
NZ722487A (en) 2022-04-29
ES2675301T3 (es) 2018-07-10
HRP20201107T8 (hr) 2020-12-11
LT3348556T (lt) 2020-08-10
EP3348556A1 (en) 2018-07-18
ECSP16070327A (es) 2018-05-31
PL3099684T3 (pl) 2018-09-28
AU2015211119A1 (en) 2016-08-11
JP2019163321A (ja) 2019-09-26
DK3348556T3 (da) 2020-08-03
US11078196B2 (en) 2021-08-03
EP3099684A1 (en) 2016-12-07
US20160207912A1 (en) 2016-07-21
HRP20201107T1 (hr) 2020-10-30
HUE050964T2 (hu) 2021-01-28
EP3099684B8 (en) 2018-07-04
ES2808978T8 (es) 2021-03-22
JP2017505779A (ja) 2017-02-23
CL2016001918A1 (es) 2017-01-13
TR201809440T4 (tr) 2018-07-23
CN106132960B (zh) 2019-12-17
PE20161393A1 (es) 2017-01-08
US20180093979A1 (en) 2018-04-05
EA032374B1 (ru) 2019-05-31
BR112016017344B1 (pt) 2023-05-16
MY187450A (en) 2021-09-22
CN111039939A (zh) 2020-04-21
CY1123374T1 (el) 2021-12-31
BR112016017344A2 (pt) 2017-10-03
JP6783900B2 (ja) 2020-11-11
RS60547B1 (sr) 2020-08-31
AU2015211119A8 (en) 2016-12-15
ME03800B (me) 2021-04-20
IL246987B (en) 2021-12-01
AP2016009347A0 (en) 2016-07-31
SG11201606108RA (en) 2016-08-30
EP3348556B1 (en) 2020-04-29
CN111039939B (zh) 2023-09-19
PT3099684T (pt) 2018-10-22

Similar Documents

Publication Publication Date Title
CY1120348T1 (el) Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
PH12015502028A1 (en) Ido inhibitors
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
MX2019007053A (es) Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EA201990400A1 (ru) Соединения и композиции и их применение
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
MX2016005128A (es) Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
EA201791249A1 (ru) Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний
BR112018070255A2 (pt) reprogramação cardíaca direta melhorada.
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
MX2019007054A (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas.
CY1124509T1 (el) Ν,ν-δις-2-μερκαπτοαιθυλο ισοφθαλαμιδιο για τη θεραπεια της νοσου toy parkinson